CASI Pharmaceuticals (CASI) Competitors

OncoCyte (NASDAQ:OCX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.

Do insiders & institutionals have more ownership in OCX or CASI?

55.3% of OncoCyte shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 2.1% of OncoCyte shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is OCX or CASI more profitable?

CASI Pharmaceuticals has a net margin of -143.18% compared to OncoCyte's net margin of -6,122.29%. CASI Pharmaceuticals' return on equity of -181.52% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OncoCyte	-6,122.29%	-269.32%	-59.71%
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%

Which has better valuation & earnings, OCX or CASI?

CASI Pharmaceuticals has higher revenue and earnings than OncoCyte. OncoCyte is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoCyte	$3.84M	19.35	-$27.78M	-$3.53	-0.74
CASI Pharmaceuticals	$31.37M	0.70	-$26.94M	-$2.55	-0.70

Does the media prefer OCX or CASI?

In the previous week, OncoCyte and OncoCyte both had 1 articles in the media. OncoCyte's average media sentiment score of 1.89 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
OncoCyte	Very Positive
CASI Pharmaceuticals	Very Positive

Do analysts rate OCX or CASI?

OncoCyte currently has a consensus target price of $6.06, suggesting a potential upside of 133.17%. CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 123.46%. Given OncoCyte's higher possible upside, analysts clearly believe OncoCyte is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoCyte	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer OCX or CASI?

CASI Pharmaceuticals received 187 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 48.56% of users gave CASI Pharmaceuticals an outperform vote while only 12.82% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
OncoCyte	Outperform Votes 15 12.82%	Underperform Votes 102 87.18%
CASI Pharmaceuticals	Outperform Votes 202 48.56%	Underperform Votes 214 51.44%

Which has more risk & volatility, OCX or CASI?

OncoCyte has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Summary

CASI Pharmaceuticals beats OncoCyte on 10 of the 16 factors compared between the two stocks.